Blog
RSS FeedPosted by Michael Wonder on 23 Jun 2020
Deciphera announces Health Canada’s authorisation of Qinlock (ripretinib) for the treatment of fourth-line gastro-intestinal stromal tumour
22 June 2020 - Qinlock significantly improved progression-free survival and showed clinically meaningful overall survival in global INVICTUS Phase 3 study. ...
Posted by Michael Wonder on 17 Jun 2020
Health Canada Approves Xtandi (enzalutamide) for the treatment of metastatic castration-sensitive prostate cancer
16 June 2020 - Xtandi is the first and only androgen receptor-axis-targeted therapy approved by Health Canada in three clinical ...
Posted by Michael Wonder on 21 May 2020
Health Canada grants market authorisation to Rozlytrek (entrectinib) for ROS1-positive, locally advanced or metastatic non-small cell lung cancer patients, not previously treated with crizotinib
20 May 2020 - Data show responses in 73% of patients who were treated with Rozlytrek. ...
Posted by Michael Wonder on 06 May 2020
AbbVie receives Health Canada approval for the combination of Venclexta (venetoclax) with obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia
5 May 2020 - Venclexta (venetoclax) plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by Health Canada for patients ...
Posted by Michael Wonder on 29 Apr 2020
Health Canada approves Rozlytrek (entrectinib) for NTRK gene fusion-positive solid tumours in locally advanced or metastatic patients
28 April 2020 - Data show more than half of trial patients across all 10 tumour types studied had responses to ...
Posted by Michael Wonder on 17 Apr 2020
Health Canada approves an extended indication for Kisqali (ribociclib) in combination treatment
16 April 2020 - Breast cancer is the most common female cancer in Canada. ...
Posted by Michael Wonder on 08 Apr 2020
Advanced Accelerator Applications announces Health Canada approval of Netspot diagnostic imaging agent kit to detect neuroendocrine tumours
7 April 2020 - Netspot is the first and only kit for the preparation of gallium (68 Ga) oxodotreotide injection for ...
Posted by Michael Wonder on 02 Mar 2020
'It's outrageous': costly cancer drugs thrown out because of one-size-fits-all packaging
1 March 2020 - Prescription drug negotiations steeped in secrecy, leaving taxpayers in the dark on costs. ...
Posted by Michael Wonder on 26 Feb 2020
Janssen receives Health Canada approval of Balversa (erdafitinib), the first FGFR kinase inhibitor for the treatment of patients with locally advanced or metastatic urothelial carcinoma with certain FGFR genetic alterations
24 February 2020 - Diagnostic testing is available to identify which patients are most likely to benefit from BALVERSA, offering a ...
Posted by Michael Wonder on 24 Jan 2020
Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with advanced renal cell carcinoma
23 January 2020 - Approval based on results of KEYNOTE-426, Where Keytruda in combination with axitinib reduced the risk of death ...
Posted by Michael Wonder on 15 Jan 2020
Health Canada approves Astellas' Xospata (gilteritinib) for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation
14 January 2020 - Xospata is the first and only targeted treatment approved by Health Canada for patients with relapsed or ...
Posted by Michael Wonder on 09 Jan 2020
New treatment approved in Canada for most common type of leukaemia
8 January 2020 - Calquence (acalabrutinib) is now available for adult patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. ...
Posted by Michael Wonder on 17 Dec 2019
Health Canada approves new indication for Erleada (apalutamide) for the treatment of metastatic castration-sensitive prostate cancer
16 December 2019 - Janssen announced today that Health Canada, following a priority review, has approved Erleada (apalutamide) for the ...
Posted by Michael Wonder on 13 Dec 2019
Novartis completes certification of initial sites in Ontario for first approved Canadian CAR-T therapy, Kymriah (tisagenlecleucel)
12 December 2019 - Ontario government to reimburse Kymriah therapy for certain patients with life-threatening cancers who are in critical need. ...
Posted by Michael Wonder on 07 Dec 2019
International collaboration among Canadian, U.S. and Australian regulators leads to new options for the treatment of cancer
6 December 2019 - Health Canada also provides an update on approvals of new drugs and medical devices for Canadians. ...